Increased endothelin-1 production in patients with chronic heart failure

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 286, Issue 3 55-3, 2004, Pages

  Parker, John D ^a,c   Thiessen, Jake J ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Congestive heart failure; Kinetic modeling

Indexed keywords

ENDOTHELIN 1; IODINE 125;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; FEMALE; HEART FAILURE; HUMAN; KINETICS; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

EID: 1342304180     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00239.2001     Document Type: Article

References (34)

1. Ando K, Hirata Y, Schichiri M, Emori T, and Marurno F. Presence of immunoreactive endothelin in human plasma. FEBS Lett 245: 164-166, 1989.
2. Anggard E, Galton S, Rae G, Thomas R, McLoughlin L, de Nucci G, and Vane J. The fate of radioiodinated endothelin-1 and endothelin-3 in the rat. J Cardiovasc Pharmacol 13, Suppl 5: S46-S49, 1989.
3. A receptors for endothelin regulation. Biochem Biophys Res Commun 238: 861-865, 1997.
4. Borgeson DD, Grantham JA, Williamson EE, Luchner A, Redfield MM, Opgenorth TJ, and Burnett JC Jr. Chronic oral endothelin type A receptor antagonism in experimental heart failure. Hypertension 31: 766-770, 1998.
5. B receptors in local clearance of endothelin-1 in rat heart: studies with the antagonists PD 155080 and BQ-788. FEBS Lett 396: 238-242, 1996.
6. Clavell AL, Mattingly MT, Stevens TL, Nir A, Wright S, Aarhus LL, Heublein DM, and Burnett JC Jr. Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction. J Clin Invest 97: 1286-1292, 1996.
7. Cody RJ, Haas GJ, Binkley PF, Capers Q, and Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 85: 504-509, 1992.
8. Dupuis J, Cernacek P, Tardif JC, Stewart DJ, Gosselin G, Dyrda I, Bonan R, and Crepeau J. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. Am Heart J 135: 614-620, 1998.
9. B receptors. J Appl Physiol 81: 1510-1515, 1996.
10. Dupuis J, Goresky CA, and Stewart DJ. Pulmonary removal and production of endothelin in the anesthetized dog. J Appl Physiol 76: 694-700, 1994.
11. Dupuis J, Rouleau JL, and Cernacek P. Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction. Circulation 98: 1684-1687, 1998.
12. Esler M, Jackman G, Bobik A, Kelleher D, Jennings G, Leonard P, Skews H, and Korner P. Determination of norepinephrine apparent release rate and clearance in humans. Life Sci 25: 1461-1470, 1979.
13. Fukuchi M and Giaid A. Expression of endothelin-1 and endothelin-converting enzyme-1 mRNAs and proteins in failing human hearts. J Cardiovasc Pharmacol 31, Suppl 1: S421-S423, 1998.
14. B receptors in rats. Biochem Biophys Res Commun 199: 1461-1465, 1994.
15. Galatius-Jensen S, Wroblewski H, Emmeluth C, Bie P, Haunso S, and Kastrup J. Plasma endothelin in congestive heart failure: effect of the ACE inhibitor, fosinopril. Cardiovasc Res 32: 1148-1154, 1996.
16. Grenier O, Pousset F, Isnard R, Kalotka H, Carayon A, Maistre G, Lechat P, Guerot C, Thomas D, and Komajda M. Captopril does not acutely modulate plasma endothelin-1 concentration in human congestive heart failure. Cardiovasc Drugs Ther 10: 561-565, 1996.
17. Iwanaga Y, Kihara Y, Hasegawa K, Inagaki K, Yoneda T, Kaburagi S, Araki M, and Sasayama S. Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats. Circulation 98: 2065-2073, 1998.
18. Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, Oechslin E, Schmitt R, Jones R, and Bertel O. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 346: 732-736, 1995.
19. Lerman A, Hildebrand FL Jr, Aarhus LL, and Burnett JC Jr. Endothelin has biological actions at pathophysiological concentrations. Circulation 83: 1808-1814, 1991.
20. Lerman A, Kubo SH, Tschumperlin LK, and Burnett JC Jr. Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. J Am Coll Cardiol 20: 849-853, 1992.
21. A-receptor antagonist. Circulation 96: 1593-1597, 1997.
22. O'Brien RF, Robbins RJ, and McMurtry IF. Endothelial cells in culture produce a vasoconstrictor substance. J Cell Physiol 132: 263-270, 1987.
23. Oie E, Vinge LE, Tonnessen T, Grogaard HK, Kjekshus H, Christensen G, Smiseth OA, and Attramadal H. Transient, isopeptide-specific induction of myocardial endothelin-1 mRNA in congestive heart failure in rats. Am J Physiol Heart Circ Physiol 273: H1727-H1736, 1997.
24. Parker J, Thiessen J, Reilly R, Tong J, Stewart D, and Pandey A. Extensive tissue uptake and slow total body elimination of endothelin-1 in humans revealed by a radiotracer technique. J Pharmacol Exp Ther 289: 261-265, 1999.
25. Pieske B, Beyermann B, Breu V, Loffler BM, Schlotthauer K, Maier LS, Schmidt-Schweda S, Just H, and Hasenfuss G. Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium. Circulation 99: 1802-1809, 1999.
26. Rodeheffer R, Lerman A, Heublein D, and Burnett J Jr. Increased plasma concentrations of endothelin in chronic heart failure in humans. Mayo Clin Proc 67: 719-724, 1992.
27. Saito Y, Nakao K, Mukoyama M, and Imura H. Increased plasma endothelin level in patients with essential hypertension. N Engl J Med 322: 205, 1990.
28. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, and Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 384: 353-355, 1996.
29. Sakai S, Miyauchi T, Sakurai T, Kasuya Y, Ihara M, Yamaguchi I, Goto K, and Sugishita Y. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. Circulation 93: 1214-1222, 1996.
30. Stewart DJ, Cernacek P, Costello KB, and Rouleau JL. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation 85: 510-517, 1992.
31. Townend J, Doran J, Jones S, and Davies M. Effect of angiotensin converting enzyme inhibition on plasma endothelin in congestive heart failure. Int J Cardiol 43: 299-304, 1994.
32. Tsutamoto T, Wada A, Hisanaga T, Maeda K, Ohnishi M, Mabuchi N, Sawaki M, Hayashi M, Fujii M, and Kinoshita M. Relationship between endothelin-1 extraction in the peripheral circulation and systemic vascular resistance in patients with severe congestive heart failure. J Am Coll Cardiol 33: 530-537, 1999.
33. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, and Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415, 1988.
34. Zolk O, Quattek J, Sitzler G, Schrader T, Nickenig G, Schnabel P, Shimada K, Takahashi M, and Bohm M. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation 99: 2118-2123, 1999.